167 related articles for article (PubMed ID: 19876785)
1. Modulation of inflammatory disease by inhibitors of leukotriene A4 hydrolase.
Fourie AM
Curr Opin Investig Drugs; 2009 Nov; 10(11):1173-82. PubMed ID: 19876785
[TBL] [Abstract][Full Text] [Related]
2. The development of novel LTA
Low CM; Akthar S; Patel DF; Löser S; Wong CT; Jackson PL; Blalock JE; Hare SA; Lloyd CM; Snelgrove RJ
Sci Rep; 2017 Mar; 7():44449. PubMed ID: 28303931
[TBL] [Abstract][Full Text] [Related]
3. Leukotriene A4 hydrolase as a target for cancer prevention and therapy.
Chen X; Wang S; Wu N; Yang CS
Curr Cancer Drug Targets; 2004 May; 4(3):267-83. PubMed ID: 15134534
[TBL] [Abstract][Full Text] [Related]
4. Drug discovery strategies for novel leukotriene A4 hydrolase inhibitors.
Röhn TA; Numao S; Otto H; Loesche C; Thoma G
Expert Opin Drug Discov; 2021 Dec; 16(12):1483-1495. PubMed ID: 34191664
[TBL] [Abstract][Full Text] [Related]
5. Identification of Human Leukotriene A4 Hydrolase Inhibitors Using Structure-Based Pharmacophore Modeling and Molecular Docking.
Audat SA; Al-Shar'i NA; Al-Oudat BA; Bryant-Friedrich A; Bedi MF; Zayed AL; Al-Balas QA
Molecules; 2020 Jun; 25(12):. PubMed ID: 32580506
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors.
Numao S; Hasler F; Laguerre C; Srinivas H; Wack N; Jäger P; Schmid A; Osmont A; Röthlisberger P; Houguenade J; Bergsdorf C; Dawson J; Carte N; Hofmann A; Markert C; Hardaker L; Billich A; Wolf RM; Penno CA; Bollbuck B; Miltz W; Röhn TA
Sci Rep; 2017 Oct; 7(1):13591. PubMed ID: 29051536
[TBL] [Abstract][Full Text] [Related]
7. Hybrid Receptor-Bound/MM-GBSA-Per-residue Energy-Based Pharmacophore Modelling: Enhanced Approach for Identification of Selective LTA4H Inhibitors as Potential Anti-inflammatory Drugs.
Appiah-Kubi P; Soliman M
Cell Biochem Biophys; 2017 Mar; 75(1):35-48. PubMed ID: 27914004
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Leukotriene A
Wu X; Sun AR; Crawford R; Xiao Y; Wang Y; Prasadam I; Mao X
Cartilage; 2024 Jun; 15(2):184-194. PubMed ID: 37086004
[TBL] [Abstract][Full Text] [Related]
9. The leukotriene B
Deng B; Lin Y; Ma S; Zheng Y; Yang X; Li B; Yu W; Xu Q; Liu T; Hao C; He R; Ding F
Kidney Int; 2017 Jul; 92(1):89-100. PubMed ID: 28318626
[TBL] [Abstract][Full Text] [Related]
10. Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A
Markert C; Thoma G; Srinivas H; Bollbuck B; Lüönd RM; Miltz W; Wälchli R; Wolf R; Hinrichs J; Bergsdorf C; Azzaoui K; Penno CA; Klein K; Wack N; Jäger P; Hasler F; Beerli C; Loetscher P; Dawson J; Wieczorek G; Numao S; Littlewood-Evans A; Röhn TA
J Med Chem; 2021 Feb; 64(4):1889-1903. PubMed ID: 33592148
[TBL] [Abstract][Full Text] [Related]
11. Leukotriene A4 Hydrolase Activation and Leukotriene B4 Production by Eosinophils in Severe Asthma.
Pal K; Feng X; Steinke JW; Burdick MD; Shim YM; Sung SS; Teague WG; Borish L
Am J Respir Cell Mol Biol; 2019 Apr; 60(4):413-419. PubMed ID: 30352167
[TBL] [Abstract][Full Text] [Related]
12. Development of a homogeneous time-resolved fluorescence leukotriene B4 assay for determining the activity of leukotriene A4 hydrolase.
Liang AM; Claret E; Ouled-Diaf J; Jean A; Vogel D; Light DR; Jones SW; Guilford WJ; Parkinson JF; Snider RM
J Biomol Screen; 2007 Jun; 12(4):536-45. PubMed ID: 17384330
[TBL] [Abstract][Full Text] [Related]
13. Determination of the contribution of cysteinyl leukotrienes and leukotriene B4 in acute inflammatory responses using 5-lipoxygenase- and leukotriene A4 hydrolase-deficient mice.
Byrum RS; Goulet JL; Snouwaert JN; Griffiths RJ; Koller BH
J Immunol; 1999 Dec; 163(12):6810-9. PubMed ID: 10586081
[TBL] [Abstract][Full Text] [Related]
14. Dual anti-inflammatory and selective inhibition mechanism of leukotriene A4 hydrolase/aminopeptidase: insights from comparative molecular dynamics and binding free energy analyses.
Appiah-Kubi P; Soliman ME
J Biomol Struct Dyn; 2016 Nov; 34(11):2418-33. PubMed ID: 26555301
[TBL] [Abstract][Full Text] [Related]
15. Isolation and structure of leukotriene-A4 hydrolase inhibitor: 8(S)-amino-2(R)-methyl-7-oxononanoic acid produced by Streptomyces diastaticus.
Parnas BL; Durley RC; Rhoden EE; Kilpatrick BF; Makkar N; Thomas KE; Smith WG; Corley DG
J Nat Prod; 1996 Oct; 59(10):962-4. PubMed ID: 8904845
[TBL] [Abstract][Full Text] [Related]
16. Leukotriene B₄-leukotriene B₄ receptor axis promotes oxazolone-induced contact dermatitis by directing skin homing of neutrophils and CD8⁺ T cells.
Lv J; Zou L; Zhao L; Yang W; Xiong Y; Li B; He R
Immunology; 2015 Sep; 146(1):50-8. PubMed ID: 25959240
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of Leukotriene A4 hydrolase inhibitors to alleviate idiopathic pulmonary fibrosis and acute lung injury.
Li X; Xie M; Lu C; Mao J; Cao Y; Yang Y; Wei Y; Liu X; Cao S; Song Y; Peng J; Zhou Y; Jiang Q; Lin G; Qin S; Qi M; Hou M; Liu X; Zhou H; Yang G; Yang C
Eur J Med Chem; 2020 Oct; 203():112614. PubMed ID: 32679453
[TBL] [Abstract][Full Text] [Related]
18. Potent and selective inhibitors of leukotriene A4 hydrolase: effects on purified enzyme and human polymorphonuclear leukocytes.
Wetterholm A; Haeggström JZ; Samuelsson B; Yuan W; Munoz B; Wong CH
J Pharmacol Exp Ther; 1995 Oct; 275(1):31-7. PubMed ID: 7562564
[TBL] [Abstract][Full Text] [Related]
19. Involvement of leukotriene B4 in murine dermatitis models.
Tsuji F; Miyake Y; Horiuchi M; Mita S
Biochem Pharmacol; 1998 Feb; 55(3):297-304. PubMed ID: 9484795
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in clinical development of leukotriene B4 pathway drugs.
Bhatt L; Roinestad K; Van T; Springman EB
Semin Immunol; 2017 Oct; 33():65-73. PubMed ID: 29042030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
